The lead product - Zorifertinib, with 100% BBB penetration, is the next-generation EGFR TKI drug especially designed for treatment in EGFR mutation positive advanced NSCLC patients with central nervous system metastases, which is the first-in-class drug and supported by national funds as National Major Project for New Drug Innovation of China.
Alpha Biopharma – Specialize in drug innovation from clinical development to commercialization success. As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovative drug.
- +86 21 63862192
- Shanghai：Unit 02-05, 11/F, East Tower, Raffles City The Bund No.1089 Dong Daming Road, Shanghai 200082, China
- Beijing：Room 2512, The Place Tower, No. 9 Guanghua Road, Chaoyang District, Beijing